Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Nov 30;8(5):239–245. doi: 10.1016/S0166-3542(87)80002-5

Intranasally administered alpha/beta interferon prevents extension of mouse hepatitis virus, strain JHM, into the brains of BALB/cByJ mice

Abigail L Smith 1,2,*, Stephen W Barthold 1, Deborah S Beck 1
PMCID: PMC7134092  PMID: 2837142

Summary

Intranasally administered alpha/beta interferon blocked extension of the coronavirus, mouse hepatitis virus, strain JHM (MHV-JHM), from the nose to the brain of BALB/cByJ mice following intranasal inoculation with the virus. Two hundred units of alpha/beta interferon were administered intranasally to BALB/cByJ mice daily over a five day period. The mice were exposed intranasally to 103 median tissue culture infectious doses of MHV-JHM on the third day of interferon treatment. Two days after virus exposure, the proportion of mice with MHV in nasal turbinates was reduced from 10 of 10 in the untreated group to 7 of 10 in the interferon-treated group, and mean titers in virus-containing noses were lower in the interferon-treated group. Five days after virus exposure, the proportion of mice with infectious virus in the brain was significantly lower in the interferon-treated group (1 of 10 mice) than in the untreated group (10 of 10 mice). Systemic infection, as measured by presence and concentration of virus in the spleen, was not affected by intranasal interferon treatment. These results suggest that intranasally administered interferon protects against local extension of MHV-JHM from nose to brain, but not against dissemination of virus to other organs, such as the spleen.

keyword: Mouse hepatitis virus, Coronavirus, Interferon

References

  1. Barthold S.W., Smith A.L. Mouse hepatitis virus S in weanling Swiss mice following intranasal inoculation. Lab. Anim. Sci. 1983;33:355–360. [PubMed] [Google Scholar]
  2. Barthold S.W., Smith A.L. Mouse hepatitis virus strain-related patterns of tissue tropism in suckling mice. Arch. Virol. 1984;81:103–112. doi: 10.1007/BF01309300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barthold S.W., Smith A.L. Response of genetically susceptible and resistant mice to intranasal inoculation with mouse hepatitis virus JHM. Virus Res. 1987;7:225–239. doi: 10.1016/0168-1702(87)90030-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barthold S.W., Smith A.L., Povar M.L. Enterotropic mouse hepatitis virus infection in nude mice. Lab. Anim. Sci. 1985;35:613–618. [PubMed] [Google Scholar]
  5. Barthold S.W., Beck D.S., Smith A.L. Mouse hepatitis virus nasoencephalopathy is dependent upon virus strain and host genotype. Arch. Virol. 1987;91:247–256. doi: 10.1007/BF01314284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burks J.S., DeVald B.L., Jankovsky L.D., Gerdes J.C. Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. Science. 1980;209:933–934. doi: 10.1126/science.7403860. [DOI] [PubMed] [Google Scholar]
  7. Gerdes J.C., Klein I., DeVald B.L. Coronavirus isolates SK and SD from multiple sclerosis patients are serologically related to murine coronaviruses A59 and JHM and human coronavirus OC43, but not to human coronavirus 229E. J. Virol. 1981;38:231–238. doi: 10.1128/jvi.38.1.231-238.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Garlinghouse L.E., Smith A.L., Holford T. The biological relationship of mouse hepatitis virus (MHV) strains and interferon: In vitro induction and sensitivities. Arch. Virol. 1984;82:19–29. doi: 10.1007/BF01309365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Garlinghouse L.E., Smith A.L. Responses of mice susceptible or resistant to lethal infection with mouse hepatitis virus, strain JHM, after exposure by a natural route. Lab. Anim. Sci. 1985;35:469–472. [PubMed] [Google Scholar]
  10. Goto N., Hirano N., Aiuchi M., Hayashi T., Fujiwara K. Nasoencephalopathy of mice infected intranasally with a mouse hepatitis virus, JHM strain. Jap. J. Exp. Med. 1977;47:59–70. [PubMed] [Google Scholar]
  11. Higgins P.G., Phillpotts R.J., Scott G.M., Wallace J., Bernhardt L.L., Tyrrell D.A.J. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob. Agents Chemother. 1983;24:713–715. doi: 10.1128/aac.24.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Amer. J. Hyg. 1938;27:493–497. [Google Scholar]
  13. Sturman L.S., Takemoto K.K. Enhanced growth of a murine coronavirus in transformed mouse cells. Infect. Immun. 1972;6:501–507. doi: 10.1128/iai.6.4.501-507.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Taguchi F., Aiuchi M., Fujiwara K. Age-dependent response of mice to a mouse hepatitis virus, MHV-S. Jap. J. Exp. Med. 1977;47:109–115. [PubMed] [Google Scholar]
  15. Taguchi F., Goto Y., Aiuchi M., Hayashi T., Fujiwara K. Pathogenesis of mouse hepatitis virus infection. The role of nasal epithelial cells as a primary target of low-virulence virus, MHV-S. Microbiol. Immunology. 1979;23:249–262. doi: 10.1111/j.1348-0421.1979.tb00461.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Turner R.B., Felton A., Kosak K., Kelsey D.K., Meschievitz C.K. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J. Infect. Dis. 1986;154:443–447. doi: 10.1093/infdis/154.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antiviral Research are provided here courtesy of Elsevier

RESOURCES